<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02011984</url>
  </required_header>
  <id_info>
    <org_study_id>recam2013_eucatech</org_study_id>
    <secondary_id>ECT024ResiCSfaRegV10</secondary_id>
    <nct_id>NCT02011984</nct_id>
  </id_info>
  <brief_title>Multicentric Non-randomized Investigation of RESISTANT Camouflage Stent-system</brief_title>
  <acronym>RECAM</acronym>
  <official_title>Multicentric Non-randomized Investigation of RESISTANT Camouflage Stent-system in Peripheral Superficial Femoral Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eucatech AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eucatech AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-randomized multicenter post-market study to confirm the long-term safety and
      effectiveness of the CE-approved Camouflage-coated self-expandable RESISTANT Camouflage stent
      system for revascularization of de novo stenotic lesions in the superficial femoral artery in
      100 compliant patients suitable for stent angioplasty.

      The CE-approved device will be used according to its intended use. Beyond the standard of
      care no further interventions are scheduled. Therefore, this trial is subject to the
      exception to the rule §23b of the German Medical Device Act (MPG), which includes the
      national implementation of EC directive 93/42/EEC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this non-randomized post-market clinical follow-up study is to confirm long-term
      safety and effectiveness of the CE-approved Camouflage-coated self expandable RESISTANT
      Camouflage stent system for revascularization of de novo stenotic lesions in superficial
      femoral artery in 120 compliant patients suitable for stent angioplasty. The primary end
      point is the target lesion revascularization after 12 months. Further follow-ups are
      scheduled at discharge, 30 days, 6 and 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Target lesion revascularization (TLR)</measure>
    <time_frame>12 months</time_frame>
    <description>Target lesion revascularization (TLR) rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>24 hours</time_frame>
    <description>Adverse Event rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>48 hours</time_frame>
    <description>Adverse Event rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>6 months</time_frame>
    <description>Adverse Event rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse Event rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>24 months</time_frame>
    <description>Adverse Event rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>24 hours</time_frame>
    <description>The ability to successfully complete stent angioplasty and achieve a residual diameter stenosis of ≤ 30 %.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>24 hours</time_frame>
    <description>Procedural success rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking Impairment Questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline in Walking Impairment Questionnaire scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking Impairment Questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in Walking Impairment Questionnaire scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford classification</measure>
    <time_frame>48 hours</time_frame>
    <description>Change from baseline in Rutherford stage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford classification</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline in Rutherford stage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford classification</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in Rutherford stage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford classification</measure>
    <time_frame>24 months</time_frame>
    <description>Change from baseline in Rutherford stage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (SF-36 questionnaire)</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in health-related quality of life (SF-36 questionnaire scores)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary patency</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of lesions that reach endpoint without TLR or with stenosis &lt; 50% on duplex ultrasonography (PSVR (Peak Systolic Velocity Ratio) &lt; 2.4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary patency</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of lesions that reach endpoint without TLR or with stenosis &lt; 50% on duplex ultrasonography (PSVR (Peak Systolic Velocity Ratio) &lt; 2.4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary patency</measure>
    <time_frame>24 months</time_frame>
    <description>Percentage of lesions that reach endpoint without TLR or with stenosis &lt; 50% on duplex ultrasonography (PSVR (Peak Systolic Velocity Ratio) &lt; 2.4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle brachial index (ABI)</measure>
    <time_frame>48 hours</time_frame>
    <description>Change from baseline in Ankle brachial index (ABI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle brachial index (ABI)</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline in Ankle brachial index (ABI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle brachial index (ABI)</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in Ankle brachial index (ABI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle brachial index (ABI)</measure>
    <time_frame>24 months</time_frame>
    <description>Change from baseline in Ankle brachial index (ABI)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>peripheral artery disease</arm_group_label>
    <description>de novo stenotic lesions in superficial femoral artery</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients with de novo stenotic lesions in the superficial femoral artery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 18 to 95 years

          -  Male or non-pregnant female

          -  De novo lesions&gt;70% or occlusions in the SFA (Superficial Femoral Artery) arteries
             suitable for stent angioplasty

          -  Max. 1 lesion within each leg should be treated as study lesions

          -  Lesions length range from ≥3 cm to ≤18 cm

          -  A patent inflow artery free from significant lesions (&gt;50 % stenosis) as confirmed by
             angiography. Treatment of target lesion acceptable after successful treatment of
             inflow artery lesions.

          -  Reference vessel diameter ≥3 mm and ≤ 7 mm

          -  Successful guide wire passage of the lesion

          -  Symptomatic peripheral artery disease (Rutherford stage 2 to 5)

          -  Patient is willing to provide informed consent and comply with the required follow-up
             visits, testing schedule, and medication regimen

        Exclusion Criteria:

          -  Patients for whom an anti-platelet therapy, anticoagulants or thrombolytics are
             contraindicated

          -  Patients presenting a lasting intraluminal thrombosis at the lesion after a
             thrombolytic therapy

          -  Perforation at the location of the angioplasty characterized by secretion of the
             contrast medium

          -  Aneurysm of the artery to be treated

          -  All common contraindications for a PTA (Percutaneous Transluminal Angioplasty)

          -  Contraindications for stent angioplasty

          -  Hypersensitivity/allergy to nickel-titanium

          -  Hypersensitivity/allergy to any of the components of the delivery &amp; dilation system

          -  Severe renal insufficiency (creatinine&gt;2.0 mg/dL or glomerular filtration rate &lt; 60
             ml/min/1.73)

          -  Uncorrected bleeding disorder

          -  Major gastrointestinal bleeding within the last 6 months.

          -  Ipsilateral intervention other than target vessel

          -  Untreated ipsilateral iliac artery stenosis &gt;70 %

          -  Previous stenting or prior surgery of the SFA

          -  In-stent restenosis

          -  Acute myocardial infarct within 72 h

          -  Less than one patent crural artery

          -  Popliteal stenosis &gt; 70 %

          -  Manifest hyperthyroidism

          -  Acute onset of symptoms

          -  Leg-threatening ischemia

          -  Multimorbid patient with poor general condition

          -  Pregnant woman or becoming pregnant in &lt; 2 yrs

          -  Living more than 100 km apart from the study center

          -  Patient actively participating in another investigational device or drug study

          -  History of hemorrhagic stroke within 3 months

          -  Previous or planned surgical or interventional procedure within 30 days of the
             procedure

          -  Acute or sub-acute thrombus in target vessel

          -  Acute vessel occlusion or sudden symptom onset

          -  Lesions in target area requiring atherectomy (or ablative devices), cutting balloons,
             cryoplasty balloons, or any other advanced device to facilitate angioplasty balloon or
             stent delivery

          -  Use of adjunctive therapies (i.e. laser, atherectomy, cryoplasty, scoring/cutting
             balloon, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Giese, Phd</last_name>
    <role>Study Chair</role>
    <affiliation>Eucatech AG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudia Marx, MD</last_name>
    <phone>00497621167333</phone>
    <phone_ext>20</phone_ext>
    <email>c.marx@clinical-evaluation.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uniklinikum Freiburg, Abteilung Röntgendiagnostik</name>
      <address>
        <city>Freiburg</city>
        <state>Baden Württemberg</state>
        <zip>79095</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wulf Euringer, M.D.</last_name>
      <phone>0049 761 270</phone>
      <phone_ext>38580</phone_ext>
      <email>wulf.euringer@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Wulf Euringer, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Gießen und Marburg, Diagnostische und Interventionelle Radiologie</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mykhaylo Burbelko, M.D.</last_name>
      <phone>0049 6421 58</phone>
      <phone_ext>65912</phone_ext>
      <email>burbelko@med.uni-marburg.de</email>
    </contact>
    <investigator>
      <last_name>Mykhaylo Burbelko, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta-Krankenhaus, Klinik für Gefäßchrirugie</name>
      <address>
        <city>Düsseldorf</city>
        <state>Nordrhein - Westfalen</state>
        <zip>40472</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf Kolvenbach, Prof.</last_name>
      <phone>0049 211 9043</phone>
      <phone_ext>301</phone_ext>
      <email>kolvenbach@vkkd-kliniken.de</email>
    </contact>
    <investigator>
      <last_name>Ralf Kolvenbach, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heinrich Braun Klinikum Zwickau, Radiologie und Neuroradiologie</name>
      <address>
        <city>Zwickau</city>
        <state>Sachsen</state>
        <zip>08060</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Thalwitzer, M.D.</last_name>
      <phone>0049 375</phone>
      <phone_ext>-4854/-4855</phone_ext>
      <email>irad@hbk-zwickau.de</email>
    </contact>
    <investigator>
      <last_name>Jörg Thalwitzer, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CCP - Istituto di Cura &quot;Città di Pavia&quot;</name>
      <address>
        <city>Pavia</city>
        <state>Lombardy</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesare Massa Saluzzo, M.D.</last_name>
      <phone>0039 3349419996</phone>
      <email>segreteria@centroendovascolare.it</email>
    </contact>
    <investigator>
      <last_name>Cesare Massa Saluzzo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2013</study_first_posted>
  <last_update_submitted>February 10, 2015</last_update_submitted>
  <last_update_submitted_qc>February 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

